



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Lutikizumab

Cat. No.:	HY-P99721
CAS No.:	1791411-57-8
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Lutikizumab (ABT-981) is an anti-IL-1 α and IL-1 β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1 α and IL-1 β . Lutikizumab can be used for the research of osteoarthritis ^[1] .								
In Vitro	ABT-981 shows simultaneously binding efficacy human IL- α and IL-1 β molecules ^[1] . ABT-981 shows highly specific binding effects to IL- α and IL-1 β over other IL-1 family members ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	Lutikizumab (0.0001-1 mg/kg, i.p., once) shows effective inhibition to the IL-6 production induced by IL-1 α and IL-1 β ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. <table><tr><td>Animal Model:</td><td>Female C57/BL6 mice with IL-1α and IL-1β injection^[1]</td></tr><tr><td>Dosage:</td><td>0.0001-1 mg/kg</td></tr><tr><td>Administration:</td><td>Intraperitoneal injection, 0.0001-1 mg/kg, once</td></tr><tr><td>Result:</td><td>Dose-dependently decreased the murine IL-6 generated by human and cynomolgus IL-1α and IL-1β.</td></tr></table>	Animal Model:	Female C57/BL6 mice with IL-1 α and IL-1 β injection ^[1]	Dosage:	0.0001-1 mg/kg	Administration:	Intraperitoneal injection, 0.0001-1 mg/kg, once	Result:	Dose-dependently decreased the murine IL-6 generated by human and cynomolgus IL-1 α and IL-1 β .
Animal Model:	Female C57/BL6 mice with IL-1 α and IL-1 β injection ^[1]								
Dosage:	0.0001-1 mg/kg								
Administration:	Intraperitoneal injection, 0.0001-1 mg/kg, once								
Result:	Dose-dependently decreased the murine IL-6 generated by human and cynomolgus IL-1 α and IL-1 β .								

REFERENCES

[1]. Lacy SE, et al. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1 α and IL-1 β . MAbs. 2015;7(3):605-19.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA